Data protection Impressum

Life sciences

Distalmotion, the Lausanne-based medtech company, has received FDA 510(k) clearance for ventral hernia repair with its DEXTER Robotic Surgery System, completing its portfolio for the four highest-volume outpatient soft tissue procedures in the United States.

Distalmotion’s DEXTER robot cleared by the FDA for ventral hernia repair

20 August 2026

Spineart, the Geneva-based medtech company specializing in spine surgery, has received FDA approval for its BAGUERA C cervical disc for one and two contiguous levels, expanding access in the United States to a motion-preserving solution for cervical disc disease.

Spineart receives FDA approval for its BAGUERA C cervical disc

20 August 2026

Oculis, the Lausanne-based biopharmaceutical company focused on ophthalmology and neuro-ophthalmology, will acquire all worldwide development and commercial rights to Privosegtor from Accure, terminating its existing license agreement.

Oculis acquires worldwide rights to its Privosegtor candidate

17 August 2026

Researchers at EPFL, with colleagues from the University of Geneva, Geneva University Hospitals and Zurich, have developed VirTues, an AI foundation model for tissue biology that analyzes tumor tissue across many cancer types, with results published in Nature.

EPFL’s VirTues AI model maps tumor tissue across cancer types

17 August 2026

AB2 Bio has received a USD 30 million payment after Japanese pharmaceutical company Nippon Shinyaku exercised its option to commercialize Tadekinig alfa in the United States, with up to USD 600 million in further milestone and royalty payments.

AB2 Bio receives USD 30 million as Nippon Shinyaku takes up US rights

3 August 2026

MoleSense and Impli, both based at the Biopôle life sciences campus, have been selected by Germany's Federal Agency for Breakthrough Innovation to develop biosensors capable of continuously measuring at least four hormones over seven days.

MoleSense and Impli selected for the SPRIND Challenge on continuous hormone monitoring

3 August 2026

Immitra Bio, based in Plan-les-Ouates in the canton of Geneva, has closed an upsized CHF 2.4 million pre-seed round to advance its scalable in-vivo gene editing platform and its lead candidate for an inherited anemia.

Immitra Bio raises CHF 2.4 million to advance its in-vivo gene editing platform

3 August 2026

HeroSupport, a Geneva-based medtech company, has announced that NYU Grossman School of Medicine is the first clinical site in the United States to participate in its SHIELD study evaluating the VENUS SHELL breast immobilization device.

HeroSupport opens its first US clinical site for the SHIELD study

3 August 2026

Pilatus Biosciences, a Biopôle-based biotech whose lead therapy originated in research conducted in Lausanne, has established a subsidiary in Hong Kong and received regulatory approval to begin a clinical trial of PLT012 in patients with advanced solid tumors.

Pilatus Biosciences takes its Lausanne-born immunotherapy to Hong Kong

3 August 2026

The .NeuroRestore center in Lausanne, led by Jocelyne Bloch and Grégoire Courtine, has been honored with the 2026 Grand Prix scientifique of the NRJ Foundation - Institut de France for its brain-spine interface that restores movement to paralyzed patients.

.NeuroRestore wins part of France’s 2026 NRJ Foundation science grand prix

13 July 2026

1 2 3 4 5 … 29